Here we report safety and efficacy findings from 2-year follow-up of the radium-223 re-treatment study. Early results from international, open-label, phase 1/2 study NCT01934790 showed that re-treatment with radium-223 was well tolerated with favorable effects on disease progression. Radium-223 dichloride (radium-223) is approved for patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no visceral disease using a dosing regimen of 6 injections (55 kBq/kg intravenously 1 injection every 4 weeks). 16 Department of Medical Oncology, GU Research Network, LLC, Omaha, Nebraska.15 Global Research and Development Statistics, Bayer HealthCare Pharmaceuticals, Whippany, New Jersey.14 Global Clinical Development, Bayer Pharma AG, Basel, Switzerland.

13 Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.

12 Nuclear Medicine Therapeutic Unit, Romagnolo Scientiﬁc Institute for the Study and Care of Cancer, IRST IRCCS, Meldola, Italy.

11 Uro-Oncology Unit, Rabin Medical Center, Davidoff Center, Petah Tikva, Israel.

10 Department of Oncology, Kuopio University Hospital, Kuopio, Finland.

9 Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

8 Division of Medical Oncology, Fondazione Istituto Nazionale Tumori Oncologia Medica Genitourinaria, Milan, Italy.

7 Division of Oncology, Rambam Health Care Campus, Haifa, Israel.

6 Department of Radiation Sciences, Cancer Center Norrlands University, Umeå, Sweden.5 Genitourinary Oncology Unit, Meir Medical Center, Kfar-Saba, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.4 Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Soﬁa Hospital, University of Cordoba, Cordoba, Spain.3 Department of Radiation Oncology, Associated Medical Professionals of New York, PLLC, Syracuse, New York.2 Department of Oncology, Akershus University Hospital, Lørenskog, Norway.1 Departments of Medicine and Urology, Tulane Cancer Center, New Orleans, Louisiana.

Radium 223 dichloride